Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy

Cancer

Volumn 116, Issue 10, 2010, Pages 2332-2342

  Han, Kyung Seok ^a,b   Jung, Dae Chul ^b   Choi, Hyuck Jae ^c   Jeong, Min Soo ^d   Cho, Kang Su ^b   Joung, Jae Young ^b   Seo, Ho Kyung ^b   Lee, Kang Hyun ^b   Chung, Jinsoo ^b  

^a Yonsei University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Asan Medical Center   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

Attenuation; Computed tomography; Contrast enhancement; Metastasis; Prognosis; Renal cell carcinoma; Response; Targeted therapy

Indexed keywords

SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; DISEASE COURSE; DRUG DELIVERY SYSTEM; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CONTRAST MEDIA; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77952576688     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25019     Document Type: Article

References (30)

1. Chow WH, Devessa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281: 1628-1631. (Pubitemid 29211773)
2. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193-205.
3. Board RE, Thistlethwaite FC, Hawkins RE. Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev. 2007;33:1-8.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
5. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
6. Bukowski R, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. 2007 ASCO Annual Meeting Proceedings, part I [abstract]. J Clin Oncol. 2007;25(18S; June 20 suppl). Abstract 5023.
7. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alpha as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 5024.
8. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540. (Pubitemid 29368255)
9. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20:289-296. (Pubitemid 34032623)
10. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
11. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alpha (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. 2007 ASCO Annual Meeting Proceedings, part I [abstract]. J Clin Oncol. 2007;25(18S; June 20 suppl). Abstract 5024.
12. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clearcell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543-550.
13. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113:1552-1558.
14. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002;20:3906-3927.
15. de Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:5548-5554.
16. Wang JH, Min PQ, Wang PJ, et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol. 2006;186:1423-1430.
17. Drevs J, Muller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002;62:4015-4022.
18. Anderson SA, Rader RK, Westlin WF, et al. Magnetic resonance contrast enhancement of neovasculature with a(v)h-targeted nanoparticles. Magn Reson Med. 2000;44:433-439.
19. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008; 7:496-501.
20. Jinzaki M, Tanimoto A, Mukai M, et al. Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr. 2000;24:835-842.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 2000;92:205-216.
22. Jung DC, Choi HJ, Kim HY, et al. Pulmonary metastasis from renal cell carcinoma: characterization using contrast-enhanced CT attenuation value measurements. J Comput Assist Tomogr. 2009;33:54-57.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
24. Hawighorst H, Weikel W, Knapstein PG, et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res. 1998;4:2305-2312.
25. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from 2 phase I studies. J Clin Oncol. 2003;21:3955-3964.
26. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572-4578.
27. Weinberg RA. Moving out: invasion and metastasis. In: Weinberg RA, The Biology of Cancer. New York: Garland Science; 2007:598-599.
28. Sardari NP, Hendriks J, Friedel G, et al. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma. Histopathology. 2007;51:354-361.
29. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028-1043.
30. Thomas AA, Rini BI, Campbell SC. Integration of surgery and systemic therapy in the management of metastatic renal cancer. Curr Urol Rep. 2009;10:35-41.